Ephx2 Deficiency Reduces COPD by Targeting Ferroptosis Mechanism

Background: Chronic obstructive pulmonary disease (COPD) represents a major global health burden, causing approximately 3.23 million deaths annually. Current therapies only alleviate symptoms and do not address underlying mechanisms, creating an unmet need for disease-modifying treatments.

Method: This preclinical study utilized Ephx2 knockout mice exposed to cigarette smoke to evaluate the impact of Ephx2 deficiency on COPD development. Key endpoints included assessment of lung inflammation, oxidative stress markers, and ferroptosis pathway activation over a 12-week exposure period.

Results: Ephx2 deficiency resulted in a 45% reduction in lung inflammation (measured by bronchoalveolar lavage fluid analysis) compared to wild-type mice, alongside a 30% decrease in markers of oxidative stress. There was a notable downregulation of ferroptosis-associated proteins, suggesting a pivotal role of this pathway in COPD pathology.

Conclusion: The findings support the hypothesis that targeting the ferroptosis mechanism through Ephx2 may present a novel therapeutic strategy for COPD management. However, given the preclinical nature of this study and reliance on animal models, additional research is required to validate these results in human populations.

Original citation address: https://www.besjournal.com/en/article/doi/10.3967/bes2026.012